Autores: Sánchez-Larsen, A. l. (Autor de correspondencia); Conde-Blanco, E.; Viloria-Alebesque, A.; Sánchez-Vizcaino Buendía, C.; Espinosa Oltra, T.; Álvarez-Noval, A.; Aledo-Serrano, A.; Martín-García, R.; Ramos-Araque, M. E.; Campos, D.; Valle-Penacoba, G.; Sierra-Gómez, A.; De Ceballos-Cerrajería, P.; Agundez-Sarasola, M.; Khawaja, M.; Hampel, K. G.; Serra-Martínez, M.; Arbos-Barber, C.;
Gómez Ibáñez, Asier;
Villino Rodríguez, Rafael Angel; Cabezudo-García, P.; Rodríguez-Lavado, I.; Príncipe, A.; Sopelana-Garay, D.
Resumen:
Background: To assess the prevalence, severity, and mortality of COVID-19 in people with epilepsy (PWE) and evaluate seizure control in PWE during and after COVID-19. Methods: Retrospective, observational, multicenter study conducted in 14 hospitals. Medical records of randomly selected PWE followed at neurology outpatient clinics were reviewed. Proportion of PWE with a positive test for SARS-CoV-2 during 2020 was calculated. Risk factors associated with COVID-19 and its morbimortality were evaluated. Results: 2751 PWE were included, mean age 48.8 years (18-99), 72.4% had focal epilepsy, and 35% were drug-refractory. COVID-19 prevalence in PWE was 5.53%, while in the Spanish population was 4.26%. Proportion of admissions to hospital, ICU, and deaths in PWE were 17.1%, 2%, and 4.61% of COVID-19 cases, while in Spanish population were 10.81%, 0.95%, and 2.57%, respectively. A severe form of COVID-19 occurred in 11.8%; dyslipidemia, institutionalization at long-term care facilities, intellectual disability, and older age were associated risk factors. Older age, hypertension, dyslipidemia, cardiac disease, and institutionalization were associated with mortality from COVID-19. Seizure control was stable in 90.1% of PWE during acute COVID-19, while 8.6% reported an increase in seizure frequency. During post-COVID-19 follow-up, 4.6% reported seizure control worsening.
